{"id":918995,"date":"2025-12-11T15:23:19","date_gmt":"2025-12-11T20:23:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/insp-shareholder-notice-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut\/"},"modified":"2025-12-11T15:23:19","modified_gmt":"2025-12-11T20:23:19","slug":"insp-shareholder-notice-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/insp-shareholder-notice-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut\/","title":{"rendered":"INSP Shareholder Notice: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

Partner Reed Kathrein Urges Investors to Contact Firm Before January 5, 2026<\/span><\/b>Lead Plaintiff Deadline<\/p>\n

\n
\n SAN FRANCISCO<\/span>
\n <\/span>, Dec. 11, 2025<\/span><\/span> \/PRNewswire\/ — National investor rights law firm Hagens Berman<\/b> alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP)<\/b>. The firm is urging INSP investors who suffered substantial losses to contact attorneys before the January 5, 2026<\/span>, Lead Plaintiff Deadline<\/b>. The lawsuit, which is currently pending in the U.S. District Court for the District of Minnesota<\/span>, alleges that Inspire Medical and its executives misled investors by concealing critical operational failures surrounding the launch of its next-generation device, the Inspire V<\/b> for obstructive sleep apnea.<\/b><\/p>\n

\n

\n
\n \"Class
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Class Period:<\/b>\u00a0Investors who purchased Inspire Medical (INSP)<\/b> securities between August 6, 2024<\/span>, and August 4, 2025<\/span><\/b>.<\/p>\n

\n Lead Plaintiff Deadline:<\/b>
\n
\n January 5, 2026<\/span>
\n <\/b>\n <\/p>\n

\n
\n Submit Your INSP Losses Now<\/a>
\n <\/b>: If you suffered a substantial loss on your INSP<\/b> investment, you are encouraged to contact Hagens Berman Partner Reed Kathrein<\/span> to discuss your legal rights:<\/p>\n

\n Visit: www.hbsslaw.com\/investor-fraud\/insp<\/a><\/b>\u00a0Email:<\/b>INSP@hbsslaw.com<\/a><\/b>Call:<\/b>844-916-0895<\/b><\/p>\n

\n The Heart of the Inspire Medical Systems (INSP) Fraud Allegations<\/b>\n <\/p>\n

The securities class action complaint details how Inspire Medical allegedly assured investors of its “operational readiness” for the Inspire V launch, claiming it was ready “to throw the switch” for full commercial rollout. These assurances, the lawsuit contends, concealed fundamental failures that made a successful launch impossible, leading to a catastrophic guidance cut and stock crash.<\/p>\n

The undisclosed operational issues that allegedly rendered the Company’s statements materially false and misleading include:<\/p>\n

\n\n\n\n\n\n
\n

\n
\n
\n Alleged<\/span>
\n
Concealment<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n The Truth Allegedly<\/span> Revealed on Aug. 4, 2025<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Impact on Business\/Stock<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Medicare &
Billing Readiness<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n The necessary software updates for Medicare
claims processing<\/b> did not take effect until July 1,
2025, meaning implanting centers could not bill
for procedures, stalling early adoption.<\/span>\n <\/p>\n<\/td>\n

\n

\n Delayed Inspire V rollout and
bottlenecked revenue generation.<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Excess Inventory
(Channel Glut)<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Customers and treatment centers held a significant
surplus of the older Inspire IV device<\/b>, impacting
demand for the new Inspire V product and
requiring an inventory “burn down.”<\/span>\n <\/p>\n<\/td>\n

\n

\n The allegedly flawed Inspire V
launch led Inspire to slash its
2025 EPS guidance by over
80%.<\/b><\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Training &
Onboarding<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n “Many centers” had not completed the essential
training, contracting, and onboarding required to
implant the new device.<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n $42.04<\/b> per share drop and 32.4%
<\/b>decline in value.<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n Hagens Berman’s Investigation of the Alleged Claims<\/b>\n <\/p>\n

“Our focus remains on the alleged concealment of two critical points: the Medicare claims software failure<\/b> and the inventory glut<\/b> of the prior Inspire IV device,” said Reed Kathrein<\/span><\/a><\/b>, <\/b>the Hagens Berman partner leading the firm’s investigation. “The suit alleges that Inspire’s stock collapse was the result of management allegedly prioritizing a narrative of seamless transition over operational reality.”<\/p>\n

\n What You Can Do?:<\/b>\u00a0If you purchased Inspire Medical (INSP)<\/b> securities during the Class Period, you may have legal options. If you wish to discuss your rights or have information that may assist our investigation, please contact Hagens Berman<\/p>\n